AbbVie, Nimble

AbbVie to acquire Nimble Therapeutics for $200m
The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq,
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline.
AbbVie buys Roche spinout Nimble Therapeutics for $200M
AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble Therapeutics,
AbbVie To Acquire Nimble Therapeutics For $200 Mln In Cash
Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along
AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline
AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.
AbbVie buying Wisconsin biotech company Nimble Therapeutics for $200 million
AbbVie Inc. said Friday it’s buying Nimble Therapeutics of Madison, Wisconsin, for $200 million. North Chicago-based AbbVie (NYSE: ABBV) said Nimble is working on creating an oral peptide “for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish
Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions from investors. AbbVie announced a $200 million deal to acquire Nimble Therapeutics,
BioPharma Dive3d
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Crain's Chicago Business3d
AbbVie to acquire Wisconsin biopharma for $200 million
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
Nimble Fold 3-in-1 Wireless Charger Review: A Modern Traveling Solution
Nimble sells the Fold 3-in-1 Wireless Charger exclusively through the Apple Store, both online and in person. It comes in ...
manilatimes13d
Nimble Introduces Qi2 Wireless Charging Collection - Available at Apple
All 3-in-1 models are Qi2 Certified and MagSafe compatible. Delivering fast, efficient wireless charging for iPhone, Apple ...
Business Insider3d
AbbVie to acquire Nimble Therapeutics for $200M cash at closing
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...
The Business Journals4d
AbbVie to buy Madison pharmaceutical tech firm for $200 million
Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash.